Delving into the Latest Updates on Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center) with Synapse

Overview

Basic Info

Drug Type

Personalized antigen vaccine, Therapeutic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsEye DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Hormone Receptor Positive Breast AdenocarcinomaHormone receptor positive HER2 negative breast cancerLocally Advanced Melanoma+ [10]

Inactive Indication-

Originator Organization

Fred Hutchinson Cancer Research Center

Active Organization

Fred Hutchinson Cancer Research Center

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma or hormone receptor positive Her2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or does not respond to treatment (refractory). Personalized neo-antigen peptide vaccine is a product combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor.

Start Date09 Jun 2022

Sponsor / Collaborator

Fred Hutchinson Cancer Research Center

ChiCTR2000035795

/ SuspendedEarly Phase 1IIT

Exploration of new technology of personalized neoantigen peptide vaccine in the adjuvant treatment of refractory colorectal cancer patients with recurrence and metastasis

Start Date30 Nov 2020

Sponsor / Collaborator

Shanghai Public Health Clinical Center

100 Clinical Results associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

Login to view more data

100 Translational Medicine associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

Login to view more data

100 Patents (Medical) associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

Login to view more data

7

Literatures (Medical) associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

15 Oct 2021·ACS Synthetic BiologyQ2 · BIOLOGY

Engineered Attenuated Salmonella typhimurium Expressing Neoantigen Has Anticancer Effects

Q2 · BIOLOGY

Article

Author: Bang, Duhee ; Ha, Sang-Jun ; Lim, Hyeonseob ; Min, Jung-Joon ; You, Sung-Hwan ; Cho, Hyunjun ; Hyun, Jungheun ; Jun, Soyeong

Neoantigen vaccines are an immunotherapy strategy for treating cancer. The vaccine degrades quickly, so the strategy must include protection and precise targeting for immune cell stimulation. In this study, we engineered attenuated Salmonella typhimurium, which is highly infiltrative to tumors, to act as a carrier for Neoantigen peptide vaccine. Our system used a constitutive promoter vector, so that a single injection of Salmonella expressing Neoantigen could be used without requiring additional induction injections. In vivo experiments on bacteria-treated mice showed that Neoantigen expressed by the engineered carrier infiltrated tumors and resulted in suppressed tumor growth, higher survival rates and longer survival times, a relative increase of CD4 and CD8 T cells, and cytokine release. These results indicate that engineered Salmonella can be used as a carrier for Neoantigen immunotherapy.

01 Aug 2021·Anticancer ResearchQ4 · MEDICINE

Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis

Q4 · MEDICINE

Article

Author: Kubo, Makoto ; Koya, Norihiro ; Morisaki, Shinji ; Onishi, Hideya ; Umebayashi, Masayo ; Tanaka, Hiroto ; Kiyotani, Kazuma ; Eto, Masatoshi ; Morisaki, Takashi ; Morisaki, Takafumi ; Yew, Poh Yin ; Takeuchi, Ario ; Tsujimura, Kenta ; Nakamura, Yusuke ; Yoshimura, Sachiko ; Monji, Keisuke ; Hirano, Tatsuya ; Nakagawa, Shinichiro

BACKGROUND/AIMNeoantigens are tumor-specific antigens that emerge due to gene mutations in tumor cells, and are highly antigenic epitopes that escape central immune tolerance in the thymus, making cancer vaccine therapy a desirable option.PATIENTS AND METHODSTumor neoantigens were predicted in 17 patients with advanced cancer. They were resistant to the standard treatment regime, and their synthetic peptides were pulsed to the patient's monocyte-derived dendritic cells (DCs), and administered to the patient's lymph nodes via ultrasound.RESULTSSome patients showed sustained tumor shrinkage after this treatment, while some did not respond, showing no ELISpot reaction. Although the number of mutations and the predicted neoantigen epitopes differed between patients, the clinical effect depended more on the presence or absence of an immune response after vaccination rather than the number of neoantigens.CONCLUSIONIntranodal neoantigen peptide-pulsed DC vaccine administration therapy has clinical and immunological efficacy and safety.

01 Mar 2021·Nature MedicineQ1 · MEDICINE

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma

Q1 · MEDICINE

Article

Author: Neuberg, Donna ; Elagina, Liudmila ; Huang, Teddy ; Olsen, Lars Rønn ; Leet, Donna E ; Liu, Jinyan ; Buchbinder, Elizabeth I ; Bachireddy, Pavan ; Hacohen, Nir ; Keskin, Derin B ; Forman, Juliet ; Li, Shuqiang ; Lee, Patrick C ; Allesøe, Rosa L ; Wu, Catherine J ; Redd, Robert A ; Peter, Lauren ; Ciantra, Zoe ; Olive, Oriol ; Holden, Rebecca ; Livak, Kenneth J ; Hu, Zhuting ; Yoon, Charles H ; Fritsch, Edward F ; Pyrdol, Jason ; Shetty, Keerthi ; Gohil, Satyen H ; Oliveira, Giacomo ; Giobbie-Hurder, Anita ; Iorgulescu, J Bryan ; Zhang, Wandi ; Wucherpfennig, Kai W ; Sarkizova, Siranush ; Sun, Jing ; Luoma, Adrienne M ; Pentelute, Bradley L ; Uduman, Mohamed ; Barouch, Dan H ; Ott, Patrick A ; Shukla, Sachet A ; Rodig, Scott

Personal neoantigen vaccines have been envisioned as an effective approach to induce, amplify and diversify antitumor T cell responses. To define the long-term effects of such a vaccine, we evaluated the clinical outcome and circulating immune responses of eight patients with surgically resected stage IIIB/C or IVM1a/b melanoma, at a median of almost 4 years after treatment with NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens per patient ( NCT01970358 ). All patients were alive and six were without evidence of active disease. We observed long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype. We also found diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. Furthermore, we detected evidence of tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma.

100 Deals associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hormone Receptor Positive Breast Adenocarcinoma	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Malignant melanoma of conjunctiva	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Melanoma recurrent	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Metastatic breast cancer	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Metastatic melanoma	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Recurrent HER2-Negative Breast Carcinoma	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Refractory Melanoma	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Unresectable Acral Lentiginous Melanoma	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Unresectable Melanoma	Phase 1	US	Fred Hutchinson Cancer Research Center	09 Jun 2022
Recurrent Non-Cutaneous Melanoma	Phase 1	US	Fred Hutchinson Cancer Research Center	01 Apr 2022